Department of Advanced Nursing Practice and Education, College of Nursing, East Carolina University, Greenville, North Carolina.
J Am Assoc Nurse Pract. 2024 Mar 1;36(3):147-150. doi: 10.1097/JXX.0000000000000942.
Opioid use disorder remains an epidemic in the United States. Buprenorphine is a Food and Drug Administration-approved medication for opioid use disorder that is associated with decreased opioid-related mortality and morbidity. Until recently, providers had to have a specialized wavier, a Drug Enforcement Agency (DEA) X, to prescribe buprenorphine for opioid use disorder. The 2023 Consolidated Appropriations Act, signed into law by President Biden, removed X waiver requirements and implements new training requirements for all new and renewing DEA registrants. This brief report outlines the history of buprenorphine prescribing regulation, reviews the recent regulatory changes and their implications for nurse practitioner buprenorphine prescribing, and concludes by considering the importance of promoting buprenorphine access.
阿片类药物使用障碍在美国仍然是一种流行疾病。丁丙诺啡是一种获得美国食品和药物管理局批准的阿片类药物使用障碍治疗药物，可降低阿片类药物相关的死亡率和发病率。直到最近，医生必须获得专门的豁免，即美国缉毒局（DEA）X 级处方，才能为阿片类药物使用障碍开出丁丙诺啡。拜登总统签署的 2023 年综合拨款法案取消了 X 级豁免要求，并为所有新的和更新的 DEA 注册者实施了新的培训要求。本简要报告概述了丁丙诺啡处方管理的历史，回顾了最近的监管变化及其对执业护士丁丙诺啡处方的影响，并最后考虑了促进丁丙诺啡使用的重要性。
